Vaccines (Jan 2021)

Seroprevalence of Antibodies against Diphtheria, Tetanus and Pertussis in Adult At-Risk Patients

  • Lise Boey,
  • Eline Bosmans,
  • Liane Braz Ferreira,
  • Nathalie Heyvaert,
  • Melissa Nelen,
  • Lisa Smans,
  • Hanne Tuerlinckx,
  • Mathieu Roelants,
  • Kathleen Claes,
  • Inge Derdelinckx,
  • Wim Janssens,
  • Chantal Mathieu,
  • Johan Van Cleemput,
  • Robin Vos,
  • Isabelle Desombere,
  • Corinne Vandermeulen

DOI
https://doi.org/10.3390/vaccines9010018
Journal volume & issue
Vol. 9, no. 1
p. 18

Abstract

Read online

Patients with chronic diseases are at increased risk of complications following infection. It remains, however, unknown to what extend they are protected against vaccine-preventable diseases. We assessed seroprevalence of antibodies against diphtheria, tetanus and pertussis to evaluate whether current vaccination programs in Belgium are adequate. Antibody titers were assessed with a bead-based multiplex assay in serum of 1052 adults with chronic diseases. We included patients with diabetes mellitus type 1 (DM1) (n = 172), DM2 (n = 77), chronic kidney disease (n = 130), chronic obstructive pulmonary disease (COPD) (n = 170), heart failure (n = 77), HIV (n = 196) and solid organ transplant (SOT) recipients (n = 230). Factors associated with seroprevalence were analysed with multiple logistic regression. We found seroprotective titers in 29% for diphtheria (≥0.1 IU/mL), in 83% for tetanus (≥0.1 IU/mL) and 22% had antibodies against pertussis (≥5 IU/mL). Seroprotection rates were higher (p p p p p < 0.01). We conclude that except for tetanus, the vast majority of at-risk patients remains susceptible to vaccine-preventable diseases such as diphtheria and pertussis.

Keywords